Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

33%(1 trials)

Phase Distribution

Ph phase_1

25%

Ph phase_2

75%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

1(25.0%)

Phase 2Efficacy & side effects

3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(1)

Detailed Status

Completed3

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (25.0%)

Phase 23 (75.0%)

Trials by Status

withdrawn125%

completed375%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_1

Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis

NCT00937027

withdrawnphase_2

Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer

NCT00003821

completedphase_2

CINJALL: Treatment for Children With Acute Lymphocytic Leukemia

NCT00176462

completedphase_2

Aminopterin in Treating Patients With Refractory Leukemia

NCT00003305

Clinical Trials (4)

Showing 4 of 4 trials

NCT00937027Phase 1

Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis

Completed

NCT00003821Phase 2

Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer

Withdrawn

NCT00176462Phase 2

CINJALL: Treatment for Children With Acute Lymphocytic Leukemia

Completed

NCT00003305Phase 2

Aminopterin in Treating Patients With Refractory Leukemia

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4